TY  - EJOU
AU  - MORETTI, SONIA 
AU  - MANCINI, FLAVIA 
AU  - BORSETTI, ALESSANDRA 

TI  - Long term immunological perturbations post DAA therapy in chronic HCV/HIV co-infected patients
T2  - BIOCELL

PY  - 2022
VL  - 46
IS  - 12
SN  - 1667-5746

AB  - Direct-acting antiviral (DAA) therapies are efficacious for the achievement of sustained virologic response (SVR) in almost all treated hepatitis C virus (HCV)-infected patients. However, the impacts of HCV eradication on immune function and chronic immune activation in the long-term remain controversial and limited, especially in patients co-infected with human immunodeficiency virus (HIV). Indeed, although restoration of many immune responses clearly can be observed, several features of immune perturbations persist over time after HCV clearance. Understanding the degree and reasons of the partial recovery of the immune system in chronic HCV/HIV co-infection after HCV elimination is pivotal to avoid disease progression and possible long-term clinical outcomes in cured patients, as well as contributing to the development of immunotherapy drug design.
KW  - HCV infection; HCV/HIV co-infection; DAA therapy; Immune activation; Inflammation
KW  -  Immune system

DO  - 10.32604/biocell.2022.022257